Other than conventional cytotoxic agents, immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway may achieve promising and durable response in patients with recurrent pancreatic NECs. Here, PDCD1 is linked to pancreatic endocrine carcinoma.